No Data
No Data
Xinbang Pharmaceutical (002390.SZ): It has developed 9 medicinal and food homologous foods, including Shanggong Tongde Huangjing tablets, Jingshan drink solid drinks, Huier high-solid drinks, and Mengxiang plant solid drinks
Gelonghui, March 27 | Xinbang Pharmaceutical (002390.SZ) said on the investor interactive platform that in terms of health products, the company has developed 9 types of medicinal homologous food products, including Shanggong Tongde Huang tablets, Jingshan solid drinks, Huier high-solid drinks, and 5 types of health products such as Shanggong Jiaotai foot bath and traditional Chinese medicine sachets.
Xinbang Pharmaceutical (002390.SZ): Produced Yixin Shu capsules, Maixukang capsules, ginkgo biloba leaves, and dengzhanhuaditin for middle-aged and elderly people
Gelonghui, March 27 | Xinbang Pharmaceutical (002390.SZ) said on the investor interactive platform that the company produced Yixinshu capsules, Maxukang capsules, ginkgo biloba leaves, and Dengzhan flower triplin are suitable for middle-aged and elderly people.
Earnings Growth of 1.1% Over 3 Years Hasn't Been Enough to Translate Into Positive Returns for Guizhou Xinbang Pharmaceutical (SZSE:002390) Shareholders
If you love investing in stocks you're bound to buy some losers. Long term Guizhou Xinbang Pharmaceutical Co., Ltd. (SZSE:002390) shareholders know that all too well, since the share price is down co
Xinbang Pharmaceutical (002390.SZ): In the first half of 2023, sales expenses accounted for about 5% of revenue, and management expenses accounted for about 6% of revenue
Gelonghui, March 15 | Xinbang Pharmaceutical (002390.SZ) said on the investor interactive platform that in the first half of 2023, sales expenses accounted for about 5% of revenue, and management expenses accounted for about 6% of revenue. The company effectively controlled various expenses through budget management. The sales expenses incurred in the first half of 2023 were 173.6613 million yuan, a decrease of about 10% over the same period of the previous year; management expenses were 206.643 million yuan, a decrease of about 8% over the same period last year. Currently, the company's various operations are smooth and orderly. The company's business involves the three major sectors of medical services, pharmaceutical distribution and pharmaceutical manufacturing, 20
Xinbang Pharmaceutical (002390.SZ): A total of 1.92% shares have been repurchased
Gelonghui, March 1, 丨 Xinbang Pharmaceutical (002390.SZ) announced that as of February 29, 2024, the cumulative number of shares repurchased by the company was 37,232,540 shares, accounting for 1.92% of the company's total share capital. The highest transaction price was 4.87 yuan/share, the lowest transaction price was 3.31 yuan/share, and the total transaction amount was 165 million yuan (excluding transaction fees).
Xinbang Pharmaceutical (002390.SZ): The recent wildfires in Guizhou Province had no impact on the company's Chinese herbal medicine planting base
Gelonghui Feb. 26丨An investor asked Xinbang Pharmaceutical (002390.SZ) on the investor interactive platform, “How much impact did the Guizhou wildfires have on the cultivation of Chinese herbal medicines in your company? Does your company have a Chinese herbal medicine planting base in the wildfire area?” The company replied that the recent wildfires in Guizhou Province had no impact on the company's Chinese herbal medicine planting base, and that the company and relevant partners will also actively take corresponding preventive measures.
No Data